Trading Terminal
Interest rates are falling, geopolitical risks are rising, and this seems like an excellent time to assess what’s next. No coincidence, then, that 20,000 people have signed up to attend the Modern Investor Summit. The event – hosted by Finimize – brings together industry-leading experts and regular folks for two days of on-point market conversations. It’s where everyday investors can gain actionable insights and inspiration, and find out about the latest trends that could change how they trade.
The 2024 line-up includes Mellody Hobson, co-CEO and president of global asset management firm Ariel Investments, and member of the board of directors for both JPMorgan Chase and Starbucks. Oh, and she’s also a former chair of the board at DreamWorks and a former member of the board of Estée Lauder. Yep: she’s the kind of business pro who puts “regular overachievers” to shame. She’ll share her insights on how to foster a long-term investment mindset, how to see short-term volatility for what it is, and the factors you need to consider when making strategic decisions.
Now, Vanguard Group is the second-biggest investment firm in the world. So it’s no small deal that President and Chief Investment Officer Gregory Davis is joining the summit. He’ll talk about his vision for Vanguard and offer insights into the firm's ETF strategy and the new funds it’s planning to launch.
And, look, a lot of the moves that investors make come down to human psychology. And when you understand your own patterns and tendencies, it can help you make way smarter decisions. That’s why Dan Ariely – the social scientist and best-selling author – is on the docket: he’ll break down why folks make the mistakes they do and help you detect your own biases.
All that, and an oracle too. Meredith Whitney, a.k.a. the "Oracle of Wall Street" will explain how you can use everyday data to help predict market trends. She’s got some simple techniques that can help you avoid the common pitfalls in data-driven strategies and make better-informed investment decisions in real-time.
Plus, pros from JPMorgan, Charles Schwab, and others, will headline sessions on just about every investing topic you can think of – alternative assets, private equity, AI startups, leveraged and inverse exchange-traded funds, even litigation investing. It’s the biggest event of the year for retail investors, after all.
Attendees will uncover the advantages (and risks) of leveraged and inverse ETFs, explore the outlook for 2025 and major trends for the next decade, and find out how AI-driven platforms are transforming retail investor decision-making. There’s even a session on how to build a winning portfolio with $10,000.
So find a minute to register (it’s free) and check out the schedule. And if you can’t watch the sessions live, don’t sweat it: you can catch up later. The recordings will be posted on youtube.com/@Finimizecom.
US
Japan
Why It Matters
The president-elect said the US would impose 25% tariffs on all goods from Canada and Mexico, and an additional 10% levy on stuff from China. The news shook up markets – sending automakers’ shares especially lower. Car makers from the US and elsewhere have built extensive factories in Mexico to take advantage of cheaper labor costs. The news provoked wider jitters too: tariffs generally spark an increase in inflation -– which, in turn, results in higher interest rates. That’s likely to slow US and global growth, creating key risks for stocks in 2025.
US consumer prices rose 2.3% in October, compared to the 2.1% the month before, according to the Federal Reserve’s (Fed’s) preferred inflation gauge. The acceleration could inspire some added caution among the central bank’s policymakers in December as they debate another possible interest rate trim. With the US economy still on relatively strong footing and its job market still robust, the market is betting on a go-slow approach from the Fed.
Millions of overweight Americans on Medicare or Medicaid would be eligible for popular weight-loss drugs like Ozempic, Wegovy, and Mounjaro. The drugs – made by Denmark-based Novo Nordisk and US-based Eli Lilly – cost nearly $1,000 a month. And according to estimates, the proposal could cost taxpayers about $35 billion over the next nine years. Still, it could be well worth the expense, as obesity causes other conditions that cost tens of billions to treat.
Japan’s currency, the yen, rose almost 3% against the US dollar last week, on expectations that the Bank of Japan would likely hike interest rates in December to cool the country’s overly warm inflation. And that’s because higher interest rates make a currency more attractive for international savers and investors. The jump in expectations also gave financial stocks a boost, because profits for banks and insurers tend to grow when rates rise.
Disclaimer: The content and materials available on this site are not intended to serve as financial, investment, trading, or any other form of advice or recommendation from Trading Terminal.
